Zhang Yanfang, Li Yongguo, Jiang Wenhui, Li Qian, Lan Yinghua
Department of Infectious Diseases, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Medicine (Baltimore). 2019 Mar;98(13):e14810. doi: 10.1097/MD.0000000000014810.
Although the prognostic value of microRNA-122 (miR-122) for hepatocellular carcinoma (HCC) patients have been evaluated by numerous studies, the results of them were not completely consistent. The present study aims to comprehensively evaluate the predicting value of miR-122 on the prognosis of patients with HCC based on all eligible literatures.
Numerous electronic databases (MEDLINE, Embase, Pubmed, Google Scholar, and China Biology Medicine disc) were applied to retrieve relevant studies. Overall survival (OS) and progression-free survival (PFS) were used as primary endpoints. All statistical analyses were performed by RevMan software version 5.3.5 and STATA software version 14.1. In addition, the results of this meta-analysis were validated by an independent dataset from the Cancer Genome Atlas (TCGA).
A total of 11 studies containing 1124 patients were included in this meta-analysis. The pooled results showed that low miR-122 expression in HCC tissues significantly associated with unfavorable OS (hazard ratio [HR] = 1.48, 95% confidence interval [CI] 1.22-1.80, P < .001) and PFS (HR = 1.54, 95% CI 1.28-1.85, P < .001) in patients with HCC. However, the expression level of miR-122 in blood did not have the ability in predicting OS (HR = 0.75, 95% CI 0.44-1.28, P = .29) and PFS (HR = 0.84, 95% CI 0.58-1.20, P = .33) of HCC. Subgroup analysis further indicated that low expression of miR-122 in tumor tissues predicted poor OS in HCC patients who received curative liver resection (HR = 2.00, 95% CI 1.08-3.70, P = .03). Analysis using TCGA dataset suggested that low miR-122 expression in HCC tissues was significantly associated with OS (HR = 1.61, 95% CI 1.13-2.27, P = .008) other than PFS (HR = 1.30, 95% CI 0.96-1.75, P = .09).
Low miR-122 expression in HCC tissues was a reliable indicator for predicting the OS of HCC patients who underwent curative resection. Owing to the disagreement between this meta-analysis and the TCGA dataset, the predictive value of miR-122 in tissues for PFS needs to be verified by future well-designed studies with large sample size.
尽管众多研究已评估了微小RNA-122（miR-122）对肝细胞癌（HCC）患者的预后价值，但其结果并不完全一致。本研究旨在基于所有符合条件的文献全面评估miR-122对HCC患者预后的预测价值。
应用多个电子数据库（MEDLINE、Embase、Pubmed、谷歌学术和中国生物医学光盘数据库）检索相关研究。总生存期（OS）和无进展生存期（PFS）用作主要终点。所有统计分析均通过RevMan 5.3.5软件版本和STATA 14.1软件版本进行。此外，本荟萃分析的结果通过来自癌症基因组图谱（TCGA）的独立数据集进行验证。
本荟萃分析共纳入11项研究，包含1124例患者。汇总结果显示，HCC组织中miR-122低表达与HCC患者不良的OS（风险比[HR]=1.48，95%置信区间[CI]1.22-1.80，P<.001）和PFS（HR=1.54，95%CI 1.28-1.85，P<.001）显著相关。然而，血液中miR-122的表达水平没有预测HCC患者OS（HR=0.75，95%CI 0.44-1.28，P=.29）和PFS（HR=0.84，95%CI 0.58-1.20，P=.33）的能力。亚组分析进一步表明，肿瘤组织中miR-122低表达预示接受根治性肝切除的HCC患者OS较差（HR=2.00，95%CI 1.08-3.70，P=.03）。使用TCGA数据集的分析表明，HCC组织中miR-122低表达与OS（HR=1.61，95%CI 1.13-2.27，P=.008）显著相关，而与PFS（HR=1.30，95%CI 0.96-1.75，P=.09）无关。
HCC组织中miR-122低表达是预测接受根治性切除的HCC患者OS的可靠指标。由于本荟萃分析与TCGA数据集之间存在分歧，miR-122在组织中对PFS的预测价值需要未来设计良好的大样本研究进行验证。
